CTLTCatalent, Inc.

NYSE catalent.com


$ 56.19 $ -0.33 (-0.58 %)    

Wednesday, 08-May-2024 15:59:57 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 56.2
$ 56.57
$ 0.00 x 0
$ 0.00 x 0
$ 56.16 - $ 56.57
$ 31.45 - $ 60.20
1,237,265
na
10.17B
$ 1.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-14-2024 12-31-2023 10-Q
3 12-08-2023 06-30-2023 10-K
4 12-08-2023 09-30-2023 10-Q
5 06-12-2023 03-31-2023 10-Q
6 02-07-2023 12-31-2022 10-Q
7 11-01-2022 09-30-2022 10-Q
8 08-29-2022 06-30-2022 10-K
9 05-03-2022 03-31-2022 10-Q
10 02-01-2022 12-31-2021 10-Q
11 11-02-2021 09-30-2021 10-Q
12 08-30-2021 06-30-2021 10-K
13 05-04-2021 03-31-2021 10-Q
14 02-02-2021 12-31-2020 10-Q
15 11-03-2020 09-30-2020 10-Q
16 08-31-2020 06-30-2020 10-K
17 05-05-2020 03-31-2020 10-Q
18 02-03-2020 12-31-2019 10-Q
19 11-05-2019 09-30-2019 10-Q
20 08-27-2019 06-30-2019 10-K
21 05-07-2019 03-31-2019 10-Q
22 02-05-2019 12-31-2018 10-Q
23 11-06-2018 09-30-2018 10-Q
24 08-28-2018 06-30-2018 10-K
25 05-01-2018 03-31-2018 10-Q
26 02-05-2018 12-31-2017 10-Q
27 11-06-2017 09-30-2017 10-Q
28 08-28-2017 06-30-2017 10-K
29 05-04-2017 03-31-2017 10-Q
30 02-06-2017 12-31-2016 10-Q
31 11-07-2016 09-30-2016 10-Q
32 08-29-2016 06-30-2016 10-K
33 05-04-2016 03-31-2016 10-Q
34 02-09-2016 12-31-2015 10-Q
35 11-03-2015 09-30-2015 10-Q
36 09-02-2015 06-30-2015 10-K
37 05-05-2015 03-31-2015 10-Q
38 02-12-2015 12-31-2014 10-Q
39 11-14-2014 09-30-2014 10-Q
40 09-08-2014 06-30-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 catalent-q3-eps-006-misses-021-estimate-sales-107b-miss-112b-estimate

Catalent (NYSE:CTLT) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.21 by 128...

 demand-soars-for-novo-nordisks-weight-loss-drug-wegovy-despite-supply-constraints-and-eli-lilly-competition

The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply con...

 novo-nordisks-dominance-in-obesity--diabetes-drug-market-backed-by-strong-pipeline-analyst-gives-outperform-rating

BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts fo...

 stephens--co-reiterates-equal-weight-on-catalent-maintains-635-price-target

Stephens & Co. analyst Jacob Johnson reiterates Catalent (NYSE:CTLT) with a Equal-Weight and maintains $63.5 price target.

 invenra-to-collaborate-with-catalent-to-co-discover-novel-bispecific-adcs

https://www.businesswire.com/news/home/20240402320363/en/

 novo-nordisk-sets-timeframe-for-its-next-gen-experimental-obesity-drug

"Novo Nordisk's optimism soars with promising early trial data for amycretin, an experimental weight loss pill. Expect ...

Core News & Articles

- Conf Call

 escalating-demand-for-obesity-drugs-creates-time-sensitive-race-for-eli-lilly-novo-nordisk

Eli Lilly's strategic collaborations with outsourcing partners for Zepbound (tirzepatide) production. Challenges persist as...

 record-high-sp-500-propels-spy-etf-to-500-billion-milestone-nvidia-tops-2-trillion-broadcom-surpasses-tesla

U.S. stock market continues bull run, hitting record highs for S&P 500 and Nasdaq 100. SPY ETF surpasses $500 billion AUM, ...

 top-stocks-not-named-nvidia-you-need-to-know-about-in-2024-heres-what-investors-think-about-them-wall-street-vs-reddit

Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed.

 eli-lilly-novo-nordisks-strategies-against-new-weight-loss-drug-competitors

Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new ob...

 rbc-capital-reiterates-sector-perform-on-catalent-maintains-635-price-target

RBC Capital analyst Sean Dodge reiterates Catalent (NYSE:CTLT) with a Sector Perform and maintains $63.5 price target.

 catalent-says-during-3-months-ended-dec-31-2023-extends-restructuring-efforts-to-reduce-costs-headcount-in-biologics--pharma-consumer-health-segments-reduced-headcount-by-about-300-employees-incurred-cumulative-employee-related-charges-of-12m

- Reuters

Core News & Articles

- Reuters

 nearly-half-of-sp-500-stocks-trade-below-50-day-moving-average-which-one-is-the-cheapest

Nearly half of S&P 500 stocks are below 50-day moving average, indicating poor market breadth. Only top 5 companies shielde...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION